Our Pricing

Complete Guide to Switching From Wegovy to Mounjaro in the UK

Switching from Wegovy to Mounjaro UK is becoming increasingly common as patients explore tirzepatide's dual-action mechanism for enhanced weight management. Many UK patients transitioning between these GLP-1 treatments seek clarity on safe dosing protocols, expected timelines, and regulatory requirements. This comprehensive guide provides expert pharmacist-verified protocols for switching from Wegovy to Mounjaro, supported by clinical trial data and UK prescriber guidelines.

Why Patients Consider Switching From Wegovy to Mounjaro UK

The decision to switch from Wegovy to Mounjaro UK typically stems from several clinical considerations. Mounjaro (tirzepatide) offers a dual-action mechanism, activating both GIP and GLP-1 receptors, whilst Wegovy (semaglutide) targets GLP-1 receptors alone. In the SURPASS-2 trial, tirzepatide demonstrated superior weight reduction compared to semaglutide, with patients losing an average of 12.4kg on the 15mg dose versus 6.2kg on semaglutide 1mg over 40 weeks [1].

Some UK patients experience plateaued weight loss on Wegovy after several months of treatment, prompting exploration of alternative therapies. Others may find Mounjaro's dosing schedule or side effect profile better suited to their individual physiology. Cost considerations also influence treatment decisions, though both medications require clinical assessment by a UK-registered prescriber before dispensing. At Cured Pharmacy, Mounjaro is available from £124.99 following approval by our clinical team, with transparent pricing displayed before your consultation begins.

Clinical Evidence Supporting the Switch

The SURPASS clinical trial programme provides robust evidence for tirzepatide's efficacy in weight management. SURPASS-3 demonstrated that participants achieved up to 15.7% body weight reduction on the 15mg dose over 72 weeks [2]. When switching from Wegovy to Mounjaro UK, patients often seek these enhanced outcomes, particularly if initial semaglutide response has diminished. However, individual results vary considerably, and no medication guarantees specific weight loss percentages. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that treatment selection must align with your medical history, current health status, and prescriber assessment.

Safe Protocol for Switching From Wegovy to Mounjaro UK

The recommended protocol for switching from Wegovy to Mounjaro UK depends on your current Wegovy dose and treatment duration. Most UK prescribers advise completing your final Wegovy injection, then initiating Mounjaro at the 2.5mg starting dose after a 7-day washout period. This approach minimises overlapping GLP-1 receptor activation whilst maintaining therapeutic continuity. Some clinicians may recommend a shorter or longer interval based on individual tolerance and side effect history [3].

If you're currently on Wegovy 2.4mg (the maximum maintenance dose), transitioning to Mounjaro 2.5mg may initially feel like a step down in potency. However, tirzepatide's dual-receptor mechanism often produces comparable or superior glycaemic control and weight reduction at lower nominal doses. The standard Mounjaro escalation schedule increases by 2.5mg increments every 4 weeks, progressing through 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg as tolerated. Your UK prescriber will determine the optimal titration speed based on your response and any adverse effects experienced during the switch.

Expected Outcomes When Switching From Wegovy to Mounjaro UK

Patients switching from Wegovy to Mounjaro UK commonly report renewed weight loss momentum within 8-12 weeks of reaching their therapeutic tirzepatide dose. Clinical data suggests that individuals who plateau on GLP-1 monotherapy may experience additional weight reduction when transitioning to dual GIP/GLP-1 agonism, though this is not universal [4]. Appetite suppression patterns may shift slightly, with some patients noting reduced food cravings or altered satiety signals during the initial transition weeks.

Gastrointestinal side effects represent the most frequent concern when switching from Wegovy to Mounjaro UK. Nausea, diarrhoea, and constipation occur in approximately 20-30% of tirzepatide users, typically during dose escalation phases. If you tolerated Wegovy well, you may experience milder side effects with Mounjaro due to prior GLP-1 exposure, though individual responses vary. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help minimise digestive discomfort. Any severe or persistent symptoms warrant immediate consultation with your prescriber.

Monitoring Progress After the Switch

UK prescribers typically recommend follow-up assessments at 4-week intervals during the first 16 weeks after switching from Wegovy to Mounjaro UK. These consultations monitor weight trajectory, side effect tolerance, and overall treatment adherence. Blood glucose levels (if you have type 2 diabetes), blood pressure, and lipid profiles may be checked periodically to assess metabolic improvements. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, ensuring safe and effective medication use under proper medical supervision.

Managing Side Effects During the Transition From Wegovy to Mounjaro UK

The side effect profile when switching from Wegovy to Mounjaro UK shares considerable overlap with standalone semaglutide therapy, though the dual-receptor mechanism may produce distinct experiences. Nausea remains the most commonly reported adverse effect, affecting roughly one in four patients during initial tirzepatide doses. This typically resolves within 2-3 weeks as your body adapts to the medication. Eating slowly, choosing bland foods, and avoiding lying down immediately after meals can provide symptomatic relief [5].

Constipation affects approximately 15-20% of Mounjaro users and may be more pronounced during the switch if you experienced similar issues on Wegovy. Increasing dietary fibre intake, maintaining adequate hydration (at least 2 litres of water daily), and regular physical activity support normal bowel function. If constipation persists beyond one week or causes significant discomfort, consult your prescriber before using over-the-counter laxatives. Rare but serious side effects include pancreatitis, gallbladder problems, and severe allergic reactions—seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or difficulty breathing.

Cost Comparison: Switching From Wegovy to Mounjaro UK Pricing

Understanding the financial implications of switching from Wegovy to Mounjaro UK helps patients make informed treatment decisions. At Cured Pharmacy, Mounjaro is available from £124.99 per month following clinical approval, with transparent pricing displayed before your consultation. We offer competitive UK pricing with no hidden fees, and first-time customers receive £20 off using code Weightlossnew. Both medications require ongoing monthly prescriptions, so budgeting for long-term treatment is essential for sustained weight management success.

The comparison table below illustrates pricing across major weight loss treatments available through Cured Pharmacy. While Mounjaro represents a premium option due to its dual-action mechanism, many patients find the enhanced efficacy justifies the investment when switching from Wegovy to Mounjaro UK. All prices include UK prescriber assessment, discreet packaging, and next-day delivery options. Remember that the cheapest option is not always the most clinically appropriate—your treatment choice should be guided by medical suitability, prescriber recommendation, and individual response rather than cost alone.

Long-Term Financial Planning

Weight management medications typically require 12-24 months of continuous use to achieve and maintain significant results. When switching from Wegovy to Mounjaro UK, factor in the cumulative annual cost and whether your budget accommodates sustained treatment. Some patients alternate between medications based on supply availability or financial circumstances, though this approach should only be undertaken under prescriber guidance. Cured Pharmacy's transparent upfront pricing—with costs displayed before consultation—enables informed financial planning without unexpected charges appearing at checkout.

How to Switch From Wegovy to Mounjaro UK Through Cured Pharmacy

The process of switching from Wegovy to Mounjaro UK through Cured Pharmacy begins with our 3-minute online clinical assessment. Our UK-registered prescribers review your medical history, current medications, weight loss goals, and previous Wegovy treatment details. You'll be asked about your current dose, treatment duration, any side effects experienced, and reasons for considering the switch. This information helps our clinical team determine whether Mounjaro is medically appropriate and safe for you [6].

Once approved, your Mounjaro prescription is dispensed from our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging. Most UK addresses receive next-day delivery when orders are placed before our daily cut-off time. Your first shipment includes the 2.5mg starting dose along with comprehensive patient information leaflets and injection technique guidance. Subsequent prescriptions are managed through your online account, with automatic reminders ensuring you never run out of medication. Our pharmacist-led support team remains available throughout your treatment journey to answer questions about switching from Wegovy to Mounjaro UK or managing any concerns that arise.

Ongoing Clinical Support

Cured Pharmacy provides continuous access to UK-registered healthcare professionals throughout your Mounjaro treatment. If you experience unexpected side effects, have questions about dose escalation, or need guidance on managing the transition from Wegovy, our clinical team is available via phone (+44 116 4646009) or secure messaging. Regular follow-up assessments ensure your treatment remains safe and effective, with dose adjustments made as clinically indicated. This level of ongoing support distinguishes comprehensive pharmacy care from simple medication dispensing, particularly important when switching from Wegovy to Mounjaro UK under medical supervision.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 64-77. [accessed 15 August 2026]
2. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583-598. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.